PCSANM's Position on US Preventative Services Task Force Revised Guideline on Prostate Cancer Screening
However, while PCSANM is pleased with the “C” recommendation embodied in the guidelines, there are weaknesses and omissions. Why a “C” but only for men 55-69? Just because the retrospective studies to date have looked more at that age group than others ignores the fact that because prostate cancer is often slow-growing, one doesn’t see the benefits of screening sometimes for more than 10-15 years. Screening early means fewer chances of developing metastatic disease during those years, so why wait until 55 to start testing? We believe that a man’s first, baseline PSA should be around the age of 45, establishing risk and personalizing future follow up. That risk stratification is critical. PSA is just a data point; it is what you do with that information that is important.
Why does the USPSTF (that worries about over treatment if a man is diagnosed) not recommend genomic testing, MRI, liquid biopsies, and other indolent disease that might lead to active surveillance rather than treatment? Why stop testing at age 70 and classify that as a “D” recommendation? Both the American Cancer Society and National Comprehensive Cancer Network talk about testing for men with at least a ten-year life expectancy– that should be the criterion, not an arbitrary age marker. And veterans, especially those who were exposed to Agent Orange, should be included in the “higher risk” population for earlier testing, along with African-American men and men with a positive family history.
US Preventative Services Task Force (USPSTF) Revised Guideline on Prostate Cancer Screening
US Preventive Services Task Force "C" Grade for Prostate Cancer Testing
Offer or provide this service for selected patients depending on individual circumstances.
A playwright with male breast cancer examines some beliefs that may influence our survival.
Combination trial missed response endpoint but exceeded historical results
Final Results from TITAN Study Confirm Apalutamide Benefit in Metastatic Castration Sensitive Prostate Cancer
The survival benefit persisted at nearly 4 years of follow-up, according to the final analysis of the phase 3 TITAN trial.
Risk is highest in men taking an alpha-blocker (ABs) medication for BPH
Alkaline water has become a popular drink trend, with many celebrities and fitness gurus touting its hydration and detoxification benefits.
Radium-223 prolongs survival in a fraction of men with bone metastatic prostate cancer (PCa).
Recent literature highlights the importance of germline genetic testing in prostate cancer (PCa) patients.
Men who underwent salvage radical prostatectomy had lower postoperative complication rates and urinary continence outcomes if the patients’ primary prostate cancer treatment was focal therapy rather than radiation therapy.
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University will collaborate with a team of community partners in a different approach to fight this health disparity.
Current trends and future perspectives